Discovery of 4-(3-aminopyrrolidinyl)-3-aryl-5-(benzimidazol-2-yl)-pyridines as potent and selective SST5 agonists for the treatment of congenital hyperinsulinism-Reference-Cited by-同舟云学术

Discovery of 4-(3-aminopyrrolidinyl)-3-aryl-5-(benzimidazol-2-yl)-pyridines as potent and selective SST5 agonists for the treatment of congenital hyperinsulinism

Published:2022-09 Issue: Volume:71 Page:128807
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Zhao Jian,Wang Shimiao,Hee Kim Sun,Han Sangdon,Rico-Bautista Elizabeth,Sturchler Emmanuel,Nguyen Julie,Tan Hannah,Staley Christine,Karin Kusnetzow Ana,Betz Stephen F.,Johns Michael,Goulet Lance,Luo Rosa,Fowler Melissa,Athanacio Jon,Markison Stacy,Scott Struthers R.,Zhu Yunfei

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference29 articles.

1. Hyperinsulinemia: An Early Indicator of Metabolic Dysfunction;Thomas;J Endocr Soc,2019

2. Congenital Hyperinsulinism: Diagnosis and Treatment Update;Demirbilek;J Clinical Res Pediatric Endocrinol,2017

3. Congenital hyperinsulinism: current status and future perspectives;Yorifuji;Ann Pediatric Endocrinol Metabolism,2014

4. Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia;Menni;Pediatrics,2001

5. Molecular mechanisms of congenital hyperinsulinism;Rahman;J Mol Endocrinol.,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism;Journal of Biological Chemistry;2023-06

2. Bridging the gaps: recent advances in diagnosis, care, and outcomes in congenital hyperinsulinism;Current Opinion in Pediatrics;2023-03-28